Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Eris Lifesciences Ltd ( (IN:ERIS) ) just unveiled an update.
Eris Lifesciences Ltd announced the acquisition of 30% of the share capital of its subsidiary, Swiss Parenterals Limited. To facilitate this acquisition, Eris will issue over 2.3 million equity shares on a preferential basis, which will also involve a material related party transaction with Mr. Naishadh Shah, a director at Swiss Parenterals. This strategic move is expected to enhance Eris’s operational capabilities and strengthen its market position.
More about Eris Lifesciences Ltd
Eris Lifesciences Ltd is a pharmaceutical company involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company primarily focuses on the Indian market, offering a variety of therapeutic solutions.
Average Trading Volume: 4,221
Technical Sentiment Signal: Buy
Current Market Cap: 226.7B INR
Find detailed analytics on ERIS stock on TipRanks’ Stock Analysis page.